R. Townsend

发表

Drug‐drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4

A. Groll, M. Engelhardt, Mark E. Jones, 2017, Transplant infectious disease : an official journal of the Transplantation Society.

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects

D. Kowalski, A. Dietz, T. Yamazaki, 2016, Clinical pharmacology in drug development.

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects

D. Kowalski, T. Yamazaki, R. Goldwater, 2016, Clinical pharmacology in drug development.

Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults

D. Kowalski, A. Groll, T. Yamazaki, 2016, Clinical pharmacology in drug development.

Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction

S. Swan, M. Hebert, I. Bekersky, 2005, Journal of clinical pharmacology.

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)

P. Bonate, W. Hope, L. Kovanda, 2016, Antimicrobial Agents and Chemotherapy.

Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P 450 3 A 4

M. Engelhardt, Mark E. Jones, N. Azie, 2017 .

The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor

R. Smulders, J. Keirns, K. Lasseter, 2013, Clinical Drug Investigation.

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

P. Bonate, D. Kowalski, L. Kovanda, 2016, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment

S. Mujais, A. Schmitt-Hoffmann, R. Townsend, 2016, Antimicrobial Agents and Chemotherapy.

Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study

D. Kowalski, R. Townsend, A. Desai, 2015, Journal of Nuclear Cardiology.

Low Dose Risperidone Every 3.8 Hours: Superior Efficacy In Treatment of Bipolar Disorders

R. Townsend, 2021 .

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults

D. Kowalski, K. Lasseter, A. Dietz, 2016, Clinical pharmacology in drug development.

Concomitant Tacrolimus and Micafungin Pharmacokinetics in Healthy Volunteers

M. Hebert, D. Blough, I. Bekersky, 2005, Journal of clinical pharmacology.

Concomitant Cyclosporine and Micafungin Pharmacokinetics in Healthy Volunteers

M. Hebert, D. Blough, I. Bekersky, 2005, Journal of clinical pharmacology.

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats

D. Andes, A. Schmitt-Hoffmann, W. Hope, 2017, Antimicrobial Agents and Chemotherapy.

Two Phase 1, Open‐Label, Mass Balance Studies to Determine the Pharmacokinetics of 14C‐Labeled Isavuconazonium Sulfate in Healthy Male Volunteers

D. Kowalski, T. Yamazaki, S. Akhtar, 2017, Clinical pharmacology in drug development.

Biodistribution of 4-[14C]Cholesterol-AmBisome following a Single Intravenous Administration to Rats

A. Zutshi, I. Bekersky, R. Townsend, 2001 .

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics

S. Mujais, D. Kowalski, S. Akhtar, 2017, European Journal of Clinical Pharmacology.

Pharmacokinetic and Safety Profiles of Repeated-dose Prophylactic Micafungin in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplantation

A. Arrieta, N. Azie, R. Townsend, 2015, Journal of pediatric hematology/oncology.

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi

P. Bonate, S. Mujais, D. Andes, 2017, Antimicrobial Agents and Chemotherapy.

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization

P. Kowey, S. Mujais, D. Kowalski, 2017, Clinical pharmacology and therapeutics.

Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects

D. Kowalski, L. Kovanda, T. Yamazaki, 2016, Clinical pharmacology in drug development.

Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects

D. Kowalski, K. Lasseter, T. Yamazaki, 2016, Clinical pharmacology in drug development.

Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment.

S. Swan, B. Davies, L. Lambrecht, 1999, Investigative radiology.

Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.

D. Kowalski, A. Schmitt-Hoffmann, T. Yamazaki, 2016, International journal of clinical pharmacology and therapeutics.

Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats.

A. Zutshi, I. Bekersky, R. Townsend, 2001, Drug metabolism and disposition: the biological fate of chemicals.

BIODISTRIBUTION OF 4-[C]CHOLESTEROL-AMBISOME FOLLOWING A SINGLE INTRAVENOUS ADMINISTRATION TO RATS

A. Zutshi, I. Bekersky, R. Townsend, 2001 .